Advertisement

Idiopathischer Morbus Parkinson und antidepressive Therapie - ein Überblick

  • M. Gastpar
  • C. Meiering
Conference paper
  • 68 Downloads

Zusammenfassung

Die Einordnung, Einchätzung und Behandlung depressiver Zustandsbilder bei Vorliegen der Grunderkrankung eines idiopathischen Morbus Parkinson hat in den letzten Jahren einen deutlichen Wandel erfahren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980) Antidepressive treatment in Parkinson’s disease. A controlled trial of the effect of nortryptyline in patients with Parkinson’s disease treated with L-Dopa. Acta Neurol Scand 62: 210–219PubMedCrossRefGoogle Scholar
  2. 2.
    Bader J-P, Hell D (1998) Parkinson-Syndrom und Depression. Fortschr Neurol Psychiatr 66: 303–312PubMedCrossRefGoogle Scholar
  3. 3.
    Bayas A, Kornhuber J, Naumann M (2001) Atypische Neuroleptika und neue Antidepressiva in der Therapie neurologischer Erkrankungen. Akt Neurol 28: 62–73CrossRefGoogle Scholar
  4. 4.
    Bunting LK, Fitzsimmons B (1991) Depression in Parkinson’s disease. J Neurosci Nurs 23: 158–164PubMedCrossRefGoogle Scholar
  5. 5.
    Caley CF, Friedman JH (1992) Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 53: 278–282PubMedGoogle Scholar
  6. 6.
    Ceravolo R, Nuti A, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, Dell’Osso L, Murri L, Bonuccelli U (2000) Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 55: 1216–1218PubMedCrossRefGoogle Scholar
  7. 7.
    Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11: 58–65PubMedCrossRefGoogle Scholar
  8. 8.
    Cummings JL (1992) Depression and Parkinson’s disease: a review. Am J Psychiatry 149: 443–454PubMedGoogle Scholar
  9. 9.
    Damier P (1999) The role of dopamine, serotonin, and noradrenaline in Parkinson’s disease. In: Wolters Ech, Scheltens PH, Berendse HW (eds) Mental Dysfunction in Parkinson’s Disease II. Academic Pharmaceutical Productions, Utrecht, pp 254–262Google Scholar
  10. 10.
    Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccini A, D’Avino C, Dell’Osso L, Bonucelli U (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clinical Neuropharmacology 24: 221–227PubMedCrossRefGoogle Scholar
  11. 11.
    Felber W (2001) Depression und Angst beim Parkinson-Syndrom. Akt Neurol 28, Sonderheft 3: 231–234Google Scholar
  12. 12.
    Hauser RA, Zesiewiscz TA (1997) Sertaline treatment of depression in Parkinson’s disease. Mov Disord 12: 756–759PubMedCrossRefGoogle Scholar
  13. 13.
    Hornykiewicz O (1982) Imbalance of brain monoamines and clinical disorders. Prog Brain Res 55: 419–429PubMedCrossRefGoogle Scholar
  14. 14.
    Klaassen T, Verhey FRJ, Snejders G (1995) Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 7: 281–286PubMedGoogle Scholar
  15. 15.
    Laitinen L (1969) Desipramine in treatment of Parkinson’s disease. A placebo-controlled study. Acta Neurol Scand 45: 109–113PubMedCrossRefGoogle Scholar
  16. 16.
    Leentjens A, Verhey F, Luijckx G-J, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Movement Disorder 15 (6): 11221–1224CrossRefGoogle Scholar
  17. 17.
    Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsics JH, Brown RP (1989) A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45–50PubMedCrossRefGoogle Scholar
  18. 18.
    Marsh GG, Markham CH (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J Neurol Neurosurg Psychiatry 36: 925–935PubMedCrossRefGoogle Scholar
  19. 19.
    Mayeux R (1990) Depression in the patient with Parkinson’s disease. J Clin Psychiatry 51 (Suppl): 20–23PubMedGoogle Scholar
  20. 20.
    Poewe W, Koller WC (2000) Evidence-based medicine review of PD treaments: the MDS project. Mov Disord 15, Suppl 3: 6Google Scholar
  21. 21.
    Poewe W, Seppi K (2001) Treatment options for depression and psychosis in Parkinson’s disease. J Neurol 248, Suppl 3: III/12-III/21CrossRefGoogle Scholar
  22. 22.
    Rascol O et al. (2002) Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 359: 1589–1598PubMedCrossRefGoogle Scholar
  23. 23.
    Richard IH, Kurlan R, and the Parkinson Study group (1997) A survey of antidepressant drug use in Parkinson’s disease. Neurology 34: 642–646Google Scholar
  24. 24.
    Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R (1989) Coexisting dementia and depression in Parkinson’s disease. Arch Neurol 46: 1284–1286PubMedCrossRefGoogle Scholar
  25. 25.
    Slaughter JR, Slaughter KA, Nichols D, Holmes S, Matrens MP (2001) Prevalence, Clinical manifestations, Etiology, and Treatment of depression in Parkinson’s Disease. J Neuropsychiatry Clin Neurosci 13 (2): 187–196PubMedCrossRefGoogle Scholar
  26. 26.
    Starkstein SE, Preziosi TJ, Bolduc PL et al. (1990) Depression in Parkinson’s Disease. J Nery Ment Dis 178: 27–31CrossRefGoogle Scholar
  27. 27.
    Steur EN (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211–213PubMedCrossRefGoogle Scholar
  28. 28.
    Steur EN, Ballering LA (1997) Moclobemide and selegeline in the treatment of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 63: 457CrossRefGoogle Scholar
  29. 29.
    Strang RR (1965) Imipramine in treatment of Parkinson’s disease: a double-blind placebo study. BMJ 2: 33–34PubMedCrossRefGoogle Scholar
  30. 30.
    Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 53: 175–179PubMedCrossRefGoogle Scholar
  31. 31.
    Tom T, Cummings JL (1998) Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs Aging 12: 55–74PubMedCrossRefGoogle Scholar
  32. 32.
    Yamamoto M (2001) Depression in Parkinson’s disease: its prevalence, diagnosis and neurochemical background. J Neurol 248, Suppl 3: III/5-III/11Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Gastpar
  • C. Meiering

There are no affiliations available

Personalised recommendations